Discovery Of Human Antibodies Against Spitting Cobra Toxins by Bojsen-Møller, Laura et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 18, 2017
Discovery Of Human Antibodies Against Spitting Cobra Toxins
Bojsen-Møller, Laura; Lohse, Brian; Harrison, Robert; Casewell, Nicholas; Andersen, Mikael Rørdam;
Laustsen, Andreas Hougaard
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Bojsen-Møller, L., Lohse, B., Harrison, R., Casewell, N., Andersen, M. R., & Laustsen, A. H. (2016). Discovery
Of Human Antibodies Against Spitting Cobra Toxins. Poster session presented at Symposium for Biological and
Life Science Students (SymBLS) 2016, Cambridge, United Kingdom.
DISCOVERY OF HUMAN ANTIBODIES AGAINST
SPITTING COBRA TOXINS
Laura Bojsen-Møller1, Brian Lohse2, Robert Harrison3, Nicholas Casewell3, Mikael R. Andersen1, Andreas H. Laustsen1
1Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark
2Department of Drug Design and Pharmacology, University of Copenhagen, Denmark
3Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
IgG scaffold IgG
scFv
The Snakebite Challenge
Current snakebite envenoming treatment options consist of animal-derived antisera [1] and are associated with
severe adverse reactions due to the heterologous nature of the animal-derived antibodies present in these antisera,
and the presence of therapeutically irrelevant antibodies [2]. The African spitting cobras are among the most
medically important snakes in sub-Saharan regions due to the severity of the clinical outcomes caused by their
cytotoxic venom, which is derived from cytotoxins of the 3FTx toxin family and PLA2 [3]. Here we report the
results of our progress in identifying human antibodies targeting relevant toxins from the venom of the black-
necked spitting cobra (Naja nigricolis).
Fig. 1: Naja nigricollis
Selection of Medically Relevant Toxins
Selecting only medically relevant venom toxins for antibody discov-
ery we avoid production of therapeutically irrelevant antibodies.
Toxin fractionation was carried out with RP-HPLC.
Fig. 2: 3FTx [4] Fig. 3: PLA2 [4]
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Future perspectives
It is our hope that this work will advance the development of re-
combinant antivenoms based on oligoclonal human antibodies that
are compatible with the human immune system, and provide better
treatment options for snakebite victims in rural parts of the tropical
world.
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